A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors

Protocol: 
AAAQ7429
Phase: 
I

A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors

Are you Eligible? (Inclusion Criteria)

1.Male or female, >= 18 years at the time of study entry
2.Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1
3.Written and signed informed consent and any locally required authorization (eg,
Health Insurance Portability and Accountability Act in the United States of
America [USA]) obtained from the subject/legal representative prior to performing
any protocol-related procedures, including screening evaluations
4.Subjects must have received and have progressed, are refractory, or are
intolerant to standard
therapy appropriate for the specific tumor type. Subjects should not have
received more than 3 prior lines of systemic therapy for recurrent or metastatic
disease (including both standard of care and investigational therapies)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States